Everything old is new again: are psychedelic medicines poised to take mental health by storm?
Acta Psychiatrica Scandinavica October 26, 2018 DOI: 10.1111/acps.12975 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Keywords | Mental health Storm Psychotherapist |
| Key points | The author recounts that when they became Director of Clinical and Translational Research at Usona Institute to pursue a new psilocybin drug indication, many mental health research colleagues reacted with disbelief, but within a year many of those same colleagues were asking how to become involved in the field. |
Abstract
Three years ago, when I accepted a position as Director of Clinical and Translational Research at Usona Institute, a non-profit medical research organization pursuing a new drug indication for the psychedelic medicine psilocybin, many of my colleagues in mental health research looked at me like I had two heads. A year later, many of these same colleagues were beginning to ask me how they could become involved in ‘this exciting new field.’
Citations in the library
Cites 14
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Regulation of the Neural Circuitry of Emotion by Compassion Meditation: Effects of Meditative Expertise PLoS One March 25, 2008
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
and 9 more in the library